Skye Bioscience Appoints New CMO, Adds Directors
Ticker: SKYE · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1516551
Sentiment: neutral
Topics: management-change, board-election, compensation
TL;DR
Skye Bioscience beefs up leadership with new CMO and board members.
AI Summary
Skye Bioscience, Inc. announced on September 3, 2024, the appointment of Dr. Michael J. Mullan as Chief Medical Officer and the election of Dr. Mullan and Ms. Sarah E. Empey to its Board of Directors. The company also disclosed compensatory arrangements for its officers, including stock options and potential bonuses.
Why It Matters
The appointment of a new Chief Medical Officer and board members suggests a strategic shift or expansion in Skye Bioscience's leadership, potentially impacting its drug development and clinical trial strategies.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate strategic shifts or internal challenges, requiring closer monitoring of the company's future performance and direction.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- Dr. Michael J. Mullan (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Ms. Sarah E. Empey (person) — Elected to Board of Directors
- September 3, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of Dr. Michael J. Mullan as Chief Medical Officer?
The filing does not detail the specific responsibilities of Dr. Mullan beyond his title as Chief Medical Officer.
What is the background of Ms. Sarah E. Empey that led to her election to the Board of Directors?
The filing does not provide background information on Ms. Sarah E. Empey.
What are the details of the compensatory arrangements for the officers mentioned?
The filing mentions compensatory arrangements for officers but does not provide specific details within the provided text.
What is the significance of the former company names listed for Skye Bioscience?
The former company names (Emerald Bioscience, Inc., Nemus Bioscience, Inc., LOAD GUARD LOGISTICS, INC.) indicate previous corporate identities and name changes for Skye Bioscience, Inc.
What is the primary business of Skye Bioscience, Inc. according to the filing?
Skye Bioscience, Inc. is classified under Pharmaceutical Preparations [2834].
Filing Stats: 1,472 words · 6 min read · ~5 pages · Grade level 11 · Accepted 2024-09-04 17:59:16
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 SKYE Nasdaq Global Market Indicate
- $475,000 — a will be paid an annual base salary of $475,000. Following the end of each calendar yea
Filing Documents
- skye-20240903.htm (8-K) — 41KB
- skye_executiveemploymentag.htm (EX-10.1) — 62KB
- a240903_skyexnrxarora.htm (EX-99.1) — 15KB
- 0001516551-24-000085.txt ( ) — 264KB
- skye-20240903.xsd (EX-101.SCH) — 2KB
- skye-20240903_def.xml (EX-101.DEF) — 2KB
- skye-20240903_lab.xml (EX-101.LAB) — 21KB
- skye-20240903_pre.xml (EX-101.PRE) — 12KB
- skye-20240903_htm.xml (XML) — 2KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On September 3, 2024, the Company issued a press release announcing Dr. Arora's appointment as Chief Medical Officer, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01, including the information contained in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the SEC made by the Company, regardless of any general incorporation language in such filings, except as shall be expressly set forth by a specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1*^+ Employment Agreement between Skye Bioscience, Inc. and Dr. Puneet Arora 99.1 Press Release , dated Sept ember 3, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document) * Portions of this exhibit have been redacted in accordance with Item 601(b)(10) of Regulation S-K. The omitted information is not material and is the type that the registrant treats as private or confidential. ^ Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. + Indicates management contract or compensatory plan.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: September 4, 2024 /s/ Punit Dhillon Name: Punit Dhillon Title: Chief Executive Officer